Scilex Holding Company Assets, Fair Value Disclosure
Scilex Holding Company (SCLX) had Assets, Fair Value Disclosure of $112.79 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-14
- 2026-06-30: Assets, Fair Value Disclosure $112.79M.
- 2026-03-31: Assets, Fair Value Disclosure $144.87M.
- 2025-12-31: Assets, Fair Value Disclosure $230.14M.
- 2025-09-30: Assets, Fair Value Disclosure $212.98M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $112.79M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $144.87M 10-Q · filed 2026-05-20 |
| 2025-12-31 | $230.14M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $212.98M 10-Q · filed 2025-11-14 |
| 2022-12-31 | $2.18M 10-K · filed 2023-03-07 |
| 2021-12-31 | $4.34M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |